Abbott Laboratories’ Navitor Transcatheter Aortic Valve Implantation System Demonstrates 97% Procedural Success and All-Cause Mortality of Just 1.

Trending News ☀️

Abbott Laboratories ($NYSE:ABT) recently released new data demonstrating the advanced effectiveness of its Navitor transcatheter aortic valve implantation system in reducing blood leakage around the implant. The system has been approved by the US FDA for use in patients with severe, symptomatic aortic stenosis who are at a high risk or greater risk of requiring open-heart surgery. The data showed that the procedure was successful in 97% of cases, with an all-cause mortality rate as low as 1.3%. This figure is especially impressive considering that it applies to cases within 30 days post-procedure.

This is encouraging news for the medical community, as it shows the system’s ability to help reduce the risks associated with surgical procedures while providing comparable results. Moreover, it shows that Abbott Laboratories is committed to providing innovative solutions in the healthcare industry to help improve patient outcomes.

Price History

O n T u e s d a y , t h e c o m p a n y ‘ s s t o c k c l i m b e d 2 % f r o m t h e p r i o r c l o s i n g p r i c e o f $ 9 9 . T h e n e w s s e n t i m e n t s u r r o u n d i n g A b b o t t i s m i x e d r i g h t n o w , w i t h m a n y i n v e s t o r s o p t i m i s t i c a b o u t i t s l a t e s t p r o d u c t b u t a l s o c a u t i o u s d u e t o t h e p o t e n t i a l d r a w b a c k s. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Abbott Laboratories. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Abbott Laboratories. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Abbott Laboratories. More…

Key Ratios Snapshot

Some of the financial key ratios for Abbott Laboratories are shown below. More…

Analysis

At GoodWhale, we conducted an analysis of ABBOTT LABORATORIES‘ fundamentals and have determined that it is classified as a ‘gorilla’, a type of company that has achieved stable and high revenue or earning growth due to its strong competitive advantage. Given this impressive performance, we believe that investors, such as individual or institutional investors, looking to invest in long-term holdings will find ABBOTT LABORATORIES a desirable target. ABBOTT LABORATORIES also boasts a high health score of 9/10 with regard to its cashflows and debt, meaning that the company is capable of paying off debt and funding future operations. This makes ABBOTT LABORATORIES an attractive option for risk-averse investors. Additionally, ABBOTT LABORATORIES is strong in dividend, growth, profitability, and medium in asset, meaning that the company is capable of providing consistent returns to investors over time. More…

Peers

Abbott Laboratories is a large, publicly traded company that manufactures and sells medical products, including diagnostics, devices, and branded generic pharmaceuticals. The company has a diversified product portfolio and a strong presence in multiple global markets. However, Abbott Laboratories faces stiff competition from other large medical companies, such as OraSure Technologies Inc, Quidel Corp, and Lucira Health Inc.

– OraSure Technologies Inc ($NASDAQ:OSUR)

OraSure Technologies Inc is a leader in developing, manufacturing, and marketing oral fluid diagnostic products. The company’s products are used for the detection of antibodies to HIV and HCV, as well as for the detection of drugs of abuse. OraSure’s products are sold in over 60 countries worldwide. The company has a market cap of 283.94M as of 2022, a Return on Equity of -8.39%.

OraSure Technologies is dedicated to improving global health by developing and delivering innovative point-of-care diagnostic solutions to meet the needs of underserved populations. The company’s products are used for the detection of infectious diseases, such as HIV and HCV, as well as for the detection of drugs of abuse. OraSure’s products are sold in over 60 countries worldwide.

– Quidel Corp ($NASDAQ:QDEL)

Quidel Corporation is a molecular diagnostics company, providing diagnostic solutions that empower patients and physicians to make better healthcare decisions. The company has a market cap of $5.18 billion and a return on equity of 22.75%. Quidel’s products are used in a variety of settings, including hospitals, physician offices, and retail pharmacies. Quidel’s products are used to diagnose a wide range of conditions, including influenza, respiratory syncytial virus, and tuberculosis. Quidel also offers a variety of point-of-care tests, including tests for pregnancy, ovulation, and infectious diseases.

– Lucira Health Inc ($NASDAQ:LHDX)

Lucira Health Inc is a medical technology company that develops and commercializes molecular diagnostics products. The company’s products are designed to enable earlier and more accurate detection of infectious diseases. Lucira Health’s products include the Lucira COVID-19 All-In-One Test Kit, which is the first FDA-cleared molecular test for the self-collection and detection of COVID-19. The company has a market cap of $46.12 million and a return on equity of -13.64%.

Summary

Abbott Laboratories‘ Navitor Transcatheter Aortic Valve Implantation System has recently demonstrated impressive results, with a 97% procedural success rate and all-cause mortality of just 1%. The system has been in clinical trials for some time and appears to be a significant advancement in implantable medical technology. For investors, this news could spark interest in Abbott Laboratories as a potential long-term investment opportunity. With the Navitor System now confirmably effective and reliable, Abbott Laboratories could benefit from potential sales revenue, cost-savings, and improved public image.

Additionally, the company may benefit from potential regulatory approval or changes in industry regulations that could open the door to further advances in implantable healthcare technology. Despite the positive news, many analysts remain cautious of the stock in light of current market conditions, and any long-term investment should be conducted with due diligence.